These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 8982647

  • 1. Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist.
    Gergen KA, Zadina JE, Paul D.
    Eur J Pharmacol; 1996 Nov 28; 316(1):33-8. PubMed ID: 8982647
    [Abstract] [Full Text] [Related]

  • 2. A Tyr-W-MIF-1 analog containing D-Pro2 discriminates among antinociception in mice mediated by different classes of mu-opioid receptors.
    Nakayama D, Watanabe C, Watanabe H, Mizoguchi H, Sakurada T, Sakurada S.
    Eur J Pharmacol; 2007 Jun 01; 563(1-3):109-16. PubMed ID: 17343845
    [Abstract] [Full Text] [Related]

  • 3. Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors.
    Gergen KA, Zadina JE, Kastin AJ, Paul D.
    Eur J Pharmacol; 1996 Mar 18; 298(3):235-9. PubMed ID: 8846821
    [Abstract] [Full Text] [Related]

  • 4. A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse.
    Watanabe H, Nakayama D, Ito K, Watanabe C, Mizoguchi H, Fujimura T, Murayama K, Kawamura S, Sato T, Sakurada C, Sakurada T, Sakurada S.
    J Pharmacol Exp Ther; 2005 Mar 18; 312(3):1075-81. PubMed ID: 15561796
    [Abstract] [Full Text] [Related]

  • 5. Involvement of spinal mu1-opioid receptors on the Tyr-d-Arg-Phe-sarcosine-induced antinociception.
    Mizoguchi H, Nakayama D, Watanabe H, Ito K, Sakurada W, Sawai T, Fujimura T, Sato T, Sakurada T, Sakurada S.
    Eur J Pharmacol; 2006 Jul 01; 540(1-3):67-72. PubMed ID: 16730704
    [Abstract] [Full Text] [Related]

  • 6. Binding of Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) and related peptides to mu 1 and mu 2 opiate receptors.
    Zadina JE, Paul D, Gergen KA, Ge LJ, Hackler L, Kastin AJ.
    Neurosci Lett; 1996 Aug 30; 215(1):65-9. PubMed ID: 8880755
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Involvement of spinal release of α-neo-endorphin on the antinociceptive effect of TAPA.
    Mizoguchi H, Kon-No T, Watanabe H, Watanabe C, Yonezawa A, Sato T, Sakurada T, Sakurada S.
    Peptides; 2013 Dec 30; 50():139-44. PubMed ID: 24126280
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tyr-W-MIF-1-induced conditioned place preference.
    Nores WL, Olson RD, Olson GA, Vaccarino AL, Bell RL, Zadina JE, Kastin AJ.
    Peptides; 1999 Dec 30; 20(4):479-84. PubMed ID: 10458518
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analgesic potency of TRIMU-5: a mixed mu 2 opioid receptor agonist/mu 1 opioid receptor antagonist.
    Tive LA, Pick CG, Paul D, Roques BP, Gacel GA, Pasternak GW.
    Eur J Pharmacol; 1992 Jun 05; 216(2):249-55. PubMed ID: 1327812
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.